Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 9/20 | 0.74 |
| ▸ | EGFR | P00533 | 13/20 | 0.72 |
| ▸ | ITK | Q08881 | 6/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9945478 | 0.88 | BTK (0.67) | BTKEGFR | |
| SCHEMBL13165493 | 0.87 | BTK (0.82) | BTKEGFRITK | |
| SCHEMBL15814594 | 0.86 | EGFR (0.74) | BTKEGFRITK | |
| SCHEMBL9945480 | 0.86 | BTK (0.69) | BTKEGFRITK | |
| SCHEMBL13165494 | 0.86 | BTK (0.84) | BTKEGFRITK | |
| SCHEMBL264837 | 0.85 | EGFR (0.54) | BTKEGFRITK | |
| SCHEMBL16370843 | 0.85 | EGFR (0.73) | BTKEGFRITK | |
| SCHEMBL2352426 | 0.85 | BTK (1.00) | BTKEGFRITK | |
| SCHEMBL2230183 | 0.85 | BTK (1.00) | BTKEGFRITK | |
| SCHEMBL13606336 | 0.84 | EGFR (1.00) | BTKEGFRITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10004741-B2 | Solid forms of an epidermal growth factor receptor kinase inhibitor | CELGENE CAR LLC (BM) | 2018-06-26 | — | — | US | disclosed |
| US-10005738-B2 | Salts of an epidermal growth factor receptor kinase inhibitor | CELGENE CAR LLC (BM) | 2018-06-26 | — | — | US | disclosed |
| US-20180072687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-15 | — | — | US | disclosed |
| US-9867824-B2 | Heterocyclic compounds and uses thereof | CELGENE CAR LLC (BM) | 2018-01-16 | — | — | US | disclosed |
| US-9868723-B2 | Mutant-selective EGFR inhibitors and uses thereof | CELGENE CAR LLC (BM) | 2018-01-16 | — | — | US | disclosed |
| US-20170281623-A1 | SOLID FORMS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR | BRISTOL-MYERS SQUIBB COMPANY | 2017-10-05 | — | — | US | disclosed |
| US-9765038-B2 | Heteroaryl compounds and uses thereof | CELGENE CAR LLC (BM) | 2017-09-19 | — | — | US | disclosed |
| US-20170217904-A1 | SALTS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR | BRISTOL-MYERS SQUIBB COMPANY | 2017-08-03 | — | — | US | disclosed |
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | Xuanzhu Pharma Co., Ltd. (CN) | 2017-04-27 | — | — | US | disclosed |
| US-20170027937-A1 | Heterocyclic Compounds and Uses Thereof | BRISTOL-MYERS SQUIBB COMPANY | 2017-02-02 | — | — | US | disclosed |
| US-9108927-B2 | Salts of an epidermal growth factor receptor kinase inhibitor | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9056839-B2 | Solid forms of an epidermal growth factor receptor kinase inhibitor | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-06-16 | — | — | US | disclosed |
| US-8975249-B2 | Heterocyclic compounds and uses thereof | CELGENE AVILOMICS RESEARCH, INC. (US) | 2015-03-10 | — | — | US | disclosed |
| US-20150025055-A1 | MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
| US-8796255-B2 | Mutant-selective EGFR inhibitors and uses thereof | Celgene Avilomics Research, Inc (US) | 2014-08-05 | — | — | US | disclosed |
| US-20130267530-A1 | SOLID FORMS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR | BRISTOL-MYERS SQUIBB COMPANY | 2013-10-10 | — | — | US | disclosed |
| US-20130267531-A1 | SALTS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-10-10 | — | — | US | disclosed |
| US-20120157426-A1 | MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120149722-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149687-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AVILA THERAPEUTICS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217904-A1 | SALTS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR | EGFR, ERBB2, ERBB4 | BTK 129/4885EGFR 1/4885ITK 288/4885 |
| US-20180072687-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | BTK 594/4885EGFR 1981/4885ITK 2697/4885 |
| US-20170112833-A1 | Tyrosine Kinase Inhibitor And Uses Thereof | EGFR, ERBB2, ABL1 | BTK 25/4885EGFR 1/4885ITK 84/4885 |
| US-20170027937-A1 | Heterocyclic Compounds and Uses Thereof | ABCG2, CYP3A5, CYP3A43 | BTK 988/4885EGFR 2849/4885ITK 2206/4885 |
| US-10005738-B2 | Salts of an epidermal growth factor receptor kinase inhibitor | EGFR, ERBB2, ERBB4 | BTK 129/4885EGFR 1/4885ITK 288/4885 |
| US-20120149687-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ABCG2, CYP3A5, CYP3A43 | BTK 988/4885EGFR 2849/4885ITK 2206/4885 |
| US-20150025055-A1 | MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF | EGFR, ERBB3, ERBB2 | BTK 46/4885EGFR 1/4885ITK 662/4885 |
| US-20170281623-A1 | SOLID FORMS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR | EGFR, ERBB2, ERBB3 | BTK 154/4885EGFR 1/4885ITK 171/4885 |
| US-20120149722-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | BTK 594/4885EGFR 1981/4885ITK 2697/4885 |
| US-20130267531-A1 | SALTS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR | EGFR, ERBB2, ERBB4 | BTK 129/4885EGFR 1/4885ITK 288/4885 |
| US-20130267530-A1 | SOLID FORMS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR | EGFR, ERBB2, ERBB3 | BTK 124/4885EGFR 1/4885ITK 174/4885 |
| US-10004741-B2 | Solid forms of an epidermal growth factor receptor kinase inhibitor | EGFR, ERBB2, ERBB3 | BTK 154/4885EGFR 1/4885ITK 171/4885 |
| US-20120157426-A1 | MUTANT-SELECTIVE EGFR INHIBITORS AND USES THEREOF | EGFR, ERBB3, ERBB2 | BTK 46/4885EGFR 1/4885ITK 662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.